Back to Stakeholders
Care Delivery & Psychedelic FacilitationClinical Care Delivery OrganizationsHealth Systems & Hospitals
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchSpecialized Academic Departments and Institutes
Care Delivery & Psychedelic FacilitationClinical Care Delivery Organizations
Care Delivery & Psychedelic Facilitation
Research, Drug Development & Manufacturing

M.D. Anderson Cancer Center

United States
3 Trials

One of the world’s leading comprehensive cancer centers, affiliated with UT Health Houston, MD Anderson Cancer Center has emerged as a site for landmark psychedelic research; the institution is conducting psilocybin-assisted psychotherapy trials in patients with advanced cancer and co-investigates NeuroGuard—a novel trial exploring psilocybin to prevent chemotherapy-induced peripheral neuropathy.

Academic Research

0 papers

Published Papers

0

Trial Involvement

3

Distinct Focus Topics

0

Latest Publication

Unknown

Quick Facts

Type
Other
HQ
United States
Website
Visit

Sponsored Trials

3
Not yet recruitingII

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

Start Date
Compounds
Psilocybin, Placebo
Active not recruitingII

TRIPS – Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

Start Date
Compounds
Psilocybin
Active not recruitingII

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

Start Date
Compounds
Psilocybin, Placebo